Perinatal exposure to phenobarbital produces a range of permanent reproductive, growth, locomoter, and learning dysfunctions in animals as well as humans. In addition, the affected individuals exhibit latently expressed (i.e., postpubertal) above normal activity levels of hepatic multicytochrome P450-dependent drug metabolizing enzymes. We report that in spite of apparent normal health for the better part of their lives, daily administration of therapeutic-like doses of phenobarbital to male and female rat pups during the first postpartum week reduced life expectancy by ~20%. Necropsy at the time of natural death revealed an associated two-to threefold increase in the incidence of tumors in barbiturate-exposed rats of both sexes and a three-to fourfold increase in urinary tract pathologies in male rats. At 2 yr of age, in agreement with an overexpression of hepatic CYP2C6 and CYP2C7, both in vitro and in vivo drug metabolism was more rapid in the phenobarbital-imprinted male and female animals. Moreover, when the senescent rats were rechallenged with a nominal dose of the barbiturate, males and females neonatally exposed to phenobarbital exhibited a dramatic overinduction of multicytochrome P450-dependent drug metabolizing enzymes as well as an overexpression of individual isoforms of cytochrome P450 implicated in enhanced susceptibility to tumorigenesis. Our findings support the growing realization that many adult diseases have their origins in early life by emphasizing that unlike adults, the new born is "plastic," and even therapeutic drugs may produce "silent" programming defects that subtly, but irrevocably, jeopardize life-long wellbeing.
genital abnormalities (2, 3) , and cross-gender identities (4) . Women perinatally exposed to the barbiturate are twice as likely to have irregular menstrual cycles and more problems during their own subsequent pregnancies (3) . As adults, both sexes score significantly lower on intelligence tests (5, 6) , have persistent learning disabilities, and are more likely to be mentally retarded (7) . The number of people perinatally exposed to phenobarbital is not trivial. Between 1950 and the late 1970s, it has been estimated that in the United States alone, 23 million children were born to mothers taking prescribed barbiturates during pregnancy (8) . Barbiturate-containing drugs are still being administered to pregnant women and newborns for a variety of often commonly occurring maladies, e.g., convulsive disorders (5) . Accordingly, ~1 of every 200 women is epileptic (9) , and 95.7% of them in the developed world are on anticonvulsant therapy (10) , which is invariably continued throughout pregnancy and lactation (11, 12) .
Of particular relevance to this study are reports demonstrating that neonatal administration of phenobarbital can induce a delayed but permanent elevation in the activities of several hepatic drug metabolizing enzymes, e.g., total cytochrome P450 (P450, CYP), ethoxycoumarin Odeethylase, ethylmorphine N-demethylase, and hexobarbital hydroxylase (1, 13, 14) . As expected, neonatal administration of barbiturates induces an almost immediate increase in the activities of the hepatic drug metabolizing enzymes and their constituent P450 isoforms CYP2B1, CYP2B2, (15) , CYP2C6, CYP3A1, and CYP3A2 (16) that declines to noninduction levels when treatment ceases. Contrary to the well-known transient effects of phenobarbital in humans (17) and animals (18) , at approximately the time of sexual maturity, a second "round" of enzyme induction occurs that persists into adulthood.
Recently, we reported that the adult increases in hepatic drug-metabolizing enzymes induced by neonatal phenobarbital may be due to an overexpression of CYP2C7 (16) . Although CYP2C7 in both sexes is neither constitutively expressed nor phenobarbital inducible until the peripubertal period (16, 19, 20) , neonatal exposure to the barbiturate produced a "silent" programming defect resulting in a delayed but permanent postpubertal ~30-50% overexpression in CYP2C7 mRNA and protein concentrations.
In the present study, we have administered phenobarbital to newborn rats at a therapeutic-like anticonvulsant dose (21, 22), which is considerably below the threshold for inducing morphologic and behavioral defects (23, 24), to determine whether or not early exposure to the barbiturate permanently alters (i.e., imprints) constitutive expression as well as the inductive response of hepatic P450s to environmental-like levels of inducing agents leading to an imperceptible but pernicious accumulation of toxic metabolites enhancing susceptibility to tumorigenesis and reducing life expectancy.
MATERIALS AND METHODS

Animals
Sprague-Dawley rats [Crl: CD (SD) BR] were housed in the University of Pennsylvania Laboratory Animal Resources facility under the supervision of veterinarians certified by the American College of Laboratory Animal Medicine and were treated according to a research protocol approved by the University's Institutional Animal Care and Use Committee. Housing and breeding procedures were as described earlier (15, 16) . On the day of parturition, all litters were mixed and randomly assigned to the dams at 10 pups/litter with a sex ratio of 1:1 or as close to that as possible. Starting within 24 h after birth and continuing daily through the first 7 days of life, all of the pups in a litter were injected subcutaneously with either 40 mg/kg body wt. of phenobarbital sodium (Sigma-Aldrich, St. Louis, MO) or an equivalent sodium concentration of the NaCl vehicle, pH 9.1, administered as 5 µl/g body wt. Thereafter, animals were maintained under conventional "clean" housing conditions in filter top cages, observed twice daily, and weighed and measured biweekly. At ~710 days of age, at least six rats of each sex were daily injected intraperitoneally with either 10 or 1 mg/kg body wt. of phenobarbital sodium for a maximum six injections and killed after 0, 64, or 136 h of treatment. A similar number of rats were treated with the barbiturate vehicle. Immediately after decapitation, the livers were removed rapidly and perfused with ice-cold saline. Each liver was quickly minced; a portion for mRNA determinations was plunged into liquid nitrogen and subsequently stored at -70°C. The remaining liver mince was used for microsome preparation (25).
Drug metabolism
Hepatic cytochrome b 5 , total P450, and hexobarbital hydroxylase were measured by established methods reviewed elsewhere (25). Hexobarbital-induced sleep times (25) were determined from 1 to 17 months of age after which time we felt there were insufficient numbers of animals to perform this occasionally lethal test.
RNA analysis
Total RNA was isolated (26) from individual livers fractionated by electrophoresis under denaturing conditions in 1.2% agarose gels containing 1× 3-(N-morpholino)-propanesulfonic acid buffer and 1.28% formaldehyde. The RNA was transferred to GeneScreen nylon membranes (DuPont/NEN, Boston, MA) by capillary transfer in 10× standard saline citrate and then fixed to the filters by ultraviolet cross-linking. Prehybridizations and hybridizations in Rapid-hyb buffer (Amersham, Arlington Heights, IL) with 32 P-labeled oligonucleotide probes were performed with high-stringency washings. The washed blots were wrapped in clear plastic and exposed to X-ray films with two intensifying screens at -70°C for 1-3 days. The nucleotide sequences of oligonucleotide probes for CYP2B1, CYP2B2 (27), CYP2C6, CYP2C7, CYP2C11, CYP2C12, CYP2C13 (28), CYP3A1 (29), and CYP3A2 (30) have been reported.
Evidence that RNA was equally loaded and transferred was obtained by equivalent intensity of ethidium bromide staining of 18S and 28S rRNA bands (31). Furthermore, the rat 18S rRNA oligonucleotide probe was used as a control to verify the consistency and integrity of RNA loading (32). Quantitation of the mRNA by laser densitometry of the X-ray films was kept within the linear range as established by slot blot hybridizations and normalized to the 18S rRNA signals in each lane as well as to two control samples repeatedly run on every blot.
Western blot analysis
Briefly, 10 µg of microsomal protein were electrophoresed on 0.75 mm thick sodium dodecyl sulfate polyacrylamide (7.5%) gels and electroblotted onto nitrocellulose filters. (34) . Quantitation of the relative protein levels was by laser densitometry of the X-ray films and by normalizing protein signals to two control samples repeatedly run on all blots.
Catalytic activity
Testosterone metabolites, including 2α-and 16α-, 7α, 15α-, and 6β-hydroxylases, reflective of the activity levels of CYP2C11, CYP2A1, CYP2A2, and CYP3A1/2 proteins, respectively; and testosterone 5α-reductase, coincidental with CYP2C12 and CYP2B1/2-dependent androstenedione 16β-hydroxylation (28, 33), were measured by radioenzymatic assays according to our reported methods (35) .
Statistical analysis
Analysis of survival data used the "R" project (http://cran.r-project.org); all other data were subjected to ANOVA. Significant differences were determined with t statistics and the Bonferroni procedure for multiple comparisons or Pearson's chi square test.
RESULTS
Neonatal exposure to phenobarbital resulted in a small (~4%), occasionally significant (P<0.05) reduction in body weights of both males and females throughout the study period. However, concurrent determinations of linear growth and obesity (i.e., Lee index) indicated no effect of the treatment. Moreover, organ weights (liver, kidneys, adrenals, seminal vesicles, or uterine) at 2 yr of age were statistically indistinguishable between vehicle control and neonatal phenobarbitaltreated rats of the same sex. In contrast, a statistically (P<0.01) larger number of barbiturateexposed rats of both sexes died at a younger age than the controls ( Fig. 1 ), resulting in a reduced mean life expectancy (Table 1) . At the time of death, necropsy results demonstrated a >2-fold increase in the incidence of tumors in barbiturate-exposed rats compared with same-sex controls ( Table 1 ). The high incidence of mammary tumors in senescent female rats (36) was responsible for a dramatic sexual dimorphism in tumor numbers. In contrast, no female had blood in her urine at the time of death, while it was apparent in 10% of vehicle-treated and 37% of phenobarbital-treated males (P<0.05), indicating an enhanced susceptibility to kidney or urinary tract pathologies in old male rats neonatally exposed to phenobarbital.
Phenobarbital, the quintessential inducing agent in numerous species, including humans, stimulates a severalfold, but transient, increase in drug metabolizing enzymes that returns to baseline levels shortly after withdrawal of the barbiturate (18) . Accordingly, we wanted to determine whether neonatal exposure to therapeutic-like levels of phenobarbital permanently altered the response of animals to the barbiturate by examining its inductive effects near the end of the natural life span of the animal. We challenged the senescent rats with either a 1 or 10 mg/kg body wt dose of phenobarbital. The lower dose is barely inductive in normal rats (37) and was an ideal dose to demonstrate an extant overinduction response in the affected animals.
However, should early exposure to phenobarbital program the rats to exhibit a subnormal responsiveness to the barbiturate in old age, the 1 mg dose would produce no differential effects and, thus, would be of no experimental value. Thus, other animals received the 10 mg dose of the barbiturate. Although far from the maximally inductive dose (18), 10 mg/kg body wt. dose was clearly inductive in control rats (37) and a subnormal response in neonatally phenobarbital treated rats would be detected when compared with controls. As it turned out, the phenobarbitalimprinted rats displayed an over-responsiveness to the barbiturate, inclining us to limit our data presentation to the 1 mg dose. Nevertheless, although the magnitude of the responses varied, both the 1 and 10 mg doses always produced a greater level of induction of P450 isoforms in the neonatal phenobarbital-treated rats of both sexes.
In addition to studying the effects of two different doses of phenobarbital, we also examined the induction response of the barbiturate after three and six injections. We wanted to determine if the rate of induction was irreversibly altered by neonatal exposure to phenobarbital. We were considering the possibility that early exposure to the barbiturate may have retarded or accelerated the induction mechanism that could be detected by measuring drug metabolizing enzymes and individual isoforms of P450 at different time points in the treatment schedule. However, what we found was that the rate of induction, whether determined after 64 or 136 h of phenobarbital treatment, was always greater in senescent males and females neonatally exposed to the barbiturate. Accordingly, for the sake of brevity, we present here only the data obtained after six injections of phenobarbital to the old rats.
Lastly, regarding the presentation of our findings, we have not reported the actual data for all of the specific P450-dependent catalytic activities (i.e., testosterone and androstenedione hydroxylations) because they were always in agreement with the mRNA and protein results and are so stated below.
The broad determinants of in vitro drug metabolism: cytochrome b 5 , total P450, and hexobarbital hydroxylase, were found at significantly greater concentrations in the livers of aged male and female rats neonatally exposed to phenobarbital than comparable age and sex-matched rats neonatally exposed to the vehicle (Table 2) . Moreover, when the rats were challenged with 1 mg phenobarbital/kg body wt. at 2 yr of age, early exposure to the barbiturate, compared with the neonatal vehicle treatment, resulted in an overinduction of cytochrome b 5 (13%), total P450 (~25%), and hexobarbital hydroxylase (50%) in both sexes. In most cases, the greater induction levels of the enzymes in the phenobarbital-imprinted rats were due to their initially higher preinduction concentrations. The exceptions being total cytochrome P450 in females and hexobarbital hydroxylase in males in which the percent increase above pre-induction levels was greater (P<0.01) in the senescent rats neonatally exposed to phenobarbital than the vehicleexposed rats.
In fact, the so-called drug-metabolizing enzymes are only functional and not structural entities the activities of which are dependent on the contribution of various isoforms of P450, each with a different affinity for the drug substrate (38) . In this regard, the near dozen rat hepatic isoforms of P450, each contributing at various degrees to the metabolism of different drugs as well as endogenous substrates (e.g., steroid hormones, prostaglandins, fatty acids) are divided into two classes: constitutive (always expressed) and inducible (poorly or not expressed in untreated rats) (18, 38) . In measuring expression levels of the major constitutive isoforms, we observed, in agreement with similar findings in 65-and 150-day-old rats (16), a permanent 30-40% overexpression (P<0.01) of CYP2C7 mRNA and protein in 2-yr-old males and females neonatally exposed to phenobarbital (Fig. 2) . The effects of neonatal phenobarbital on the major constituent isoform CYP2C6 was limited to females. Early exposure to the barbiturate resulted in a 29% overexpression of CYP2C6 mRNA when measured at 2 yr of age (data not presented).
[Although CYP2C6 protein levels reflected mRNA concentrations, the only commercially available antibody against the isoform crossreacts with five other hepatic P450 isoforms (info@gentest), compromising our findings and thus, not presented.] In contrast, neonatal exposure to the barbiturate produced no long-lasting changes in expression levels and dependent catalytic activities of the more abundant constitutive isoforms CYP2C11, CYP2C12, CYP2C13, and CYP3A2.
Although it is possible that a lifetime of overexpressed CYP2C7 and CYP2C6 results in the continuous, above normal accumulation of reactive intermediary metabolites (38, 39) promoting tumorigenesis and a shortened life expectancy, we also considered the contribution of inducible isoforms of P450 known to be implicated in drug and environmentally induced cancers (18, 40, 41) . Accordingly, we challenged the senescent animals with a subtherapeutic dose of phenobarbital (1 mg/kg body wt.) that equaled ~1% of its optimal inductive dose (42) . Whereas this nominal dose of phenobarbital stimulated a minimal induction of CYP2B1 and CYP2B2 (the most responsive phenobarbital inducible isoforms; refs 18, 37, 38) in the control rats, the inductive response was severalfold greater in the 2-yr-olds of both sexes neonatally-treated with the barbiturate (Fig. 3) In addition, the responsiveness of the inducible CYP3A1 and malespecific CYP3A2 was (P<0.01) greater in the senescent, phenobarbital-imprinted rats. Induction of CYP2C6 in females and CYP2C7 (Fig. 2) in both sexes were ~40% and ~30% greater, respectively, in aged rats neonatally exposed to the barbiturate. This overinduction of individual P450 isoforms is reflected in the above normal activities of the drug metabolizing enzyme system (Table 2) .
To demonstrate that the phenobarbital-imprinted overexpression of multi-P450-dependent drug metabolizing enzymes and specific P450 isoforms was not simply a curious "test-tube" phenomenon, we measured the pharmacologically functional endpoint of hexobarbital-induced sleep times. If the permanent overexpression of hexobarbital hydroxylase and contributing P450 isoforms was biologically significant, we should observe a commensurate decline in hexobarbital-induced sleep times. Indeed, we did observe a permanent, postpubertal decline in sleep times in both male and female rats neonatally exposed to phenobarbital (Fig. 4). [The general increasing sleep times in all the aging males is independent of phenobarbital effects, but rather is a result of a senescence-induced decline in male-specific CYP2C11 expression (43); the isoform normally comprising >50% of the total hepatic P450s in adult male rats (44) .]
DISCUSSION
We have proposed that perinatal exposure to seemingly innocuous therapeutic levels of drugs could be the origins of subtle, but permanent, biochemical defects having long-term health consequences. It is likely that the most dramatic, and possibly "ultimate," clinical consequence of any treatment is its effect on health and longevity. Accordingly, we treated neonates with therapeutic-like doses of phenobarbital for the first week of life. Thereafter, twice daily observations revealed no evidence of morphologic, functional, or behavioral abnormalities throughout the better part of the lives of the animals. General measures of well-being as determined by body weight gain, linear growth, and obesity were normal. Moreover, at the time of death, gross examination of the major organs, e.g., liver, kidneys, lungs, heart, gastrointestinal tract, showed that they were for the most part similar to those found in age-and sex-matched controls. Yet, in spite of this apparent normalcy, a statistically (P<0.01) larger number of barbiturate-exposed rats of both sexes died at a younger age than the controls resulting in a ~20% reduced mean life expectancy. At the time of death, necropsy results demonstrated a two-to threefold increase in the incidence of tumors in barbiturate-exposed rats compared with same-sex controls. Whereas, 10% of vehicle-treated male neonates exhibited urinary tract pathologies at the time of death, three to four times that number were found in senescent males exposed to phenobarbital during the first week of life.
We observed that the phenobarbital-imprinted elevation in drug metabolism reported in young adults (1, 13, 14) was truly permanent. Hexobarbital hydroxylase activity at 2 yr of age remained 35-60% higher in neonatally phenobarbital-treated male and female rats, respectively, with a concurrent decline in the pharmacologic effectiveness (i.e., hexobarbital-induced sleep times) of the drug. In agreement with reports in young rats (16), we found a persistent 30-40% (P<0.01) overexpression of CYP2C7 in 2-yr-old rats neonatally exposed to the barbiturate. In addition, we observed a permanent above normal (~30%) expression of CYP2C6 in senescent females neonatally treated with phenobarbital. The fact that CYP2C7 comprises ~20% of the total hepatic P450 in female rats and ~7% in male rats (45) and CYP2C6 represents ~40% of the total hepatic P450 in female rats (19) could account, in part, for the observed overexpression of drug metabolizing enzymes in both sexes of affected rats.
Since the hepatic P450 profile of a person could effect his or her longevity (46) , it seemed reasonable that a lifetime of overexpressed CYP2C7 and CYP2C6 resulting in the continuous, above normal accumulation of reactive intermediary metabolites (38, 39) could promote tumorigenesis and a shorter life expectancy in our phenobarbital-exposed rats. In addition, we also considered the contribution of inducible isoforms of P450 known to be implicated in drugand environmentally induced cancers (18, 40, 41) and response levels to phenobarbital challenge are generally age independent (47) . Accordingly, we challenged the senescent animals with a subtherapeutic dose of phenobarbital (1 mg/kg) that equaled ~1% of its optimal inductive dose (42), evoking the insidious dangers to human health of comparable low levels of harmful environmental compounds. Whereas this nominal dose of the barbiturate stimulated a minimal induction of CYP2B1 and CYP2B2 in the control rats, the inductive response was severalfold greater in the 2-yr-olds, neonatally treated with the barbiturate. In addition, the responsiveness of the inducible CYP3A1 and constitutive CYP2C7, CYP2C6, and CYP3A2 to phenobarbital challenge remained considerably (P<0.01) greater in the senescent barbiturate-imprinted rats.
The results suggest that exposure of newborns to even therapeutic-like doses of phenobarbital can program the liver to continuously overexpress constitutive P450s and, when challenged by a lifetime of drug consumption and environmental insults, the liver overexpresses inducible isoforms, all contributing to the long-term, virtual "disconnect" effect of increasing accumulation of toxic metabolites (e.g., carcinogens) enhancing tumorigenesis and reducing life expectancy. Coincidentally, phenobarbital is a known carcinogen that can increase the metabolism of innocuous compounds into carcinogenic and toxic metabolites (40, 41) . In fact, perinatal exposure to the barbiturate has been reported to subsequently increase the risk of cancer in adult rats (48, 49) and children (50) . The capacity of phenobarbital to induce tumor formation is related, in part, to its ability to affect DNA methylation (51) . Whereas genomic methylation patterns are reprogrammed during differentiation and maintained thereafter (52), teratogeninduced changes in DNA methylation of promoter regions can cause congenital defects (53) by altering critical genomic transcription (51) . Although speculative, it is possible that neonatal phenobarbital produces "silent" epigenetic defects (i.e., altered DNA methylation) that contribute to a delayed, but permanent, elevation in P450 expression and an associated susceptibility to tumorigenesis. Whether these results are applicable to the millions of people perinatally exposed to the barbiturate is uncertain, but a published survey of the offspring of mothers administered phenobarbital during pregnancy reported that the treatment was associated with a 2.5 times higher number of deaths by early adulthood (54) .
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This work was supported by National Institutes of Health Grant HD-16358. We appreciate the generosity of Drs. Marika Rönneholm, Agneta Mode, and Jan-Åke Gustafsson in supplying the antibody to rat CYP2C12/13 and of Dr. Stelvio M. Bandiera in supplying the antibody to rat CYP2C7. We also thank Alka Agrawal for excellent technical assistance and Andrew Liaw for statistical analyses support. or its vehicle measured after rechallenge with 1 mg/kg body wt. of the barbiturate for 6 consecutive days at 2 years of age. Data points are means ±SD for 6 or more rats, presented as a percentage of mean value of group expressing greatest induction; designated 100%. *P < 0.01, compared with neonatal vehicle-treated rats of the same sex. consecutive days at 2 years of age. Data points are means ±SD for 6 or more rats, presented as a percentage of mean value of group expressing greatest induction; designated 100%. CYP3A2 graph is limited to males because the isoform is expressed only in that sex (25, 33). Whereas nonconstituent CYP3A1 can be induced in both sexes (47) , the antibody used in western analysis is highly reactive to CYP3A2 protein, and thus findings presented for CYP3A1 is for females alone.
Although not presented, the response of CYP3A1 mRNA in male livers were statistically indistinguishable from that depicted for females, i.e., greater induction in PB-imprinted rats of both sexes. Moreover, CYP2B1/2-dependent androstenedione 16β-hydroxylase was in complete agreement with mRNA and protein levels (not presented). T6β-OH, CYP3A1/2-dependent testosterone 6β-hydroxylase. ND, not detectable. *P < 0.01, compared with neonatal vehicle-treated rats of same sex. 
